New combo attack on HPV throat cancer before standard treatment

This study is testing if a new HPV vaccine (PRGN-2009) combined with an immunotherapy drug (pembrolizumab) can boost the immune system's attack on cancer cells in people newly diagnosed with HPV-positive throat cancer. The goal is to see if this short treatment before standard surgery or chemoradiation can increase cancer-fighting immune cells in the tumor and potentially improve long-term survival. About 16 participants will receive the drug and two vaccine shots over a few weeks before starting their planned cancer treatment.